< Back

Galapagos creates new warrant plan

01 May 2015 at 18:00 CET

Mechelen, Belgium; 1 May 2015 - Galapagos NV (Euronext: GLPG) announced today that its Board of Directors created 625,740 warrants under a new warrant plan for the benefit of employees, directors and an independent consultant of the Company and its subsidiaries.

On 30 April 2015, the Board of Directors of Galapagos approved the "Warrant Plan 2015" within the framework of the authorized capital.  Under this warrant plan, 625,740 warrants were created, subject to acceptances.

The warrants created under Warrant Plan 2015 were offered on 30 April 2015, mainly to employees of Galapagos and its subsidiaries and in secondary order to its directors and an independent consultant.  The offer of warrants to directors has been pre-approved by the Annual Shareholders' Meeting held on 28 April 2015.

The warrants have an exercise term of eight years as of the date of the offer and have an exercise price of €28.75 (the average closing price of the share on Euronext Brussels during the thirty days preceding the date of the offer).  The warrants are not transferable and can in principle not be exercised prior to the end of the third calendar year after the calendar year in which they were granted to the beneficiaries.  Each warrant gives the right to subscribe to one new Galapagos share.  Should the warrants be exercised, Galapagos will apply for the listing of the resulting new shares on a regulated stock market.  The warrants as such will not be listed on any stock market.

To date, Galapagos' total share capital amounts to €166,996,209.57; the total number of securities conferring voting rights is 30,870,677, which is also the total number of voting rights (the "denominator"), and all securities conferring voting rights and all voting rights are of the same category.  The total number of rights (warrants) to subscribe to not yet issued securities conferring voting rights is 3,019,305, which equals the total number of voting rights that may result from the exercise of these warrants, and excludes the 625,740 warrants of Warrant Plan 2015 which were created subject to acceptances.  Galapagos does not have any convertible bonds or shares without voting rights outstanding.

About Galapagos
Galapagos (Euronext: GLPG; OTC: GLPYY) is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 25 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications.  In the field of inflammation, AbbVie and Galapagos signed a collaboration agreement for the development and commercialization of filgotinib.  Filgotinib is an orally-available, selective inhibitor of JAK1 for the treatment of rheumatoid arthritis and potentially other inflammatory diseases, currently in Phase 2B studies in RA and in Phase 2 in Crohn's disease.  Galapagos reported good activity and a favorable safety profile at 12 weeks in both the DARWIN 1 and 2 trials in RA.  AbbVie and Galapagos also signed a collaboration agreement in cystic fibrosis to develop and commercialize molecules that address mutations in the CFTR gene.  Potentiator GLPG1837 is currently in a Phase 1 trial, and corrector GLPG2222 is at the pre-clinical candidate stage.  GLPG1205, a first-in-class inhibitor of GPR84 and fully-owned by Galapagos, is currently being tested in a Phase 2 proof-of-concept trial in ulcerative colitis patients.  GLPG1690, a fully proprietary, first-in-class inhibitor of autotaxin, has shown favorable safety in a Phase 1 trial and is expected to enter Phase 2 in idiopathic pulmonary fibrosis.  The Galapagos Group, including fee-for-service subsidiary Fidelta, has approximately 400 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, and Croatia.  Further information at: www.glpg.com

CONTACT

Galapagos NV
Elizabeth Goodwin, Head of Corporate Communications & IR
Tel: +31 6 2291 6240
ir@glpg.com

This release may contain forward-looking statements, including, without limitation, statements concerning anticipated progress, objectives and expectations regarding the commercial potential of our product candidates, intended product development, clinical activity timing, and other objectives and explanations, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "believes," "anticipates," "expects," "intends," "plans," "seeks," "estimates," "may," "will," "could," "stands to," "continues," "we believe," "we intend," as well as similar expressions. Such forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, financial condition, performance or achievements of Galapagos, or industry results, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with competitive developments, clinical trial and product development activities, regulatory approval requirements and estimating the commercial potential of our product candidates. Given these uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. These forward-looking statements speak only as of the date of publication of this document. Galapagos expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Downloads

Title Download